6.1, 6.2, 6.3 Number of PBS prescriptions dispensed for asthma medicines per 100,000 people, 2013–14

Exported from METEOR

(AIHW's Metadata Online Registry)

© Australian Institute of Health and Welfare 2024

This product, excluding the AIHW logo, Commonwealth Coat of Arms and any material owned by a third party or protected by a trademark, has been released under a Creative Commons BY 4.0 (CC BY 4.0) licence. Excluded material owned by third parties may include, for example, design and layout, images obtained under licence from third parties and signatures. We have made all reasonable efforts to identify and label material owned by third parties.

You may distribute, remix and build on this website’s material but must attribute the AIHW as the copyright holder, in line with our attribution policy. The full terms and conditions of this licence are available at https://creativecommons.org/licenses/by/4.0/.

Enquiries relating to copyright should be addressed to info@aihw.gov.au.

Enquiries or comments on the METEOR metadata or download should be directed to the METEOR team at meteor@aihw.gov.au.

# ​6.1, 6.2, 6.3 Number of PBS prescriptions dispensed for asthma medicines per 100,000 people, 2013–14

|  |
| --- |
| Identifying and definitional attributes |
| Metadata item type: | Indicator |
| Indicator type: | Indicator |
| Short name: | Asthma medicines dispensing, 2013-14 |
| METEOR identifier: | 611645 |
| Registration status: |  [National Health Performance Authority (retired)](https://meteor-uat.aihw.gov.au/RegistrationAuthority/10), Retired 01/07/2016[Australian Commission on Safety and Quality in Health Care](https://meteor-uat.aihw.gov.au/RegistrationAuthority/2), Standard 23/11/2016 |
| Description: | Number of prescriptions dispensed for asthma medicines per 100,000 people, age standardised. Data are disaggregated by the area in which the person lives. |
| Indicator set: | [Australian Atlas of Healthcare Variation](https://meteor-uat.aihw.gov.au/content/623427)  [National Health Performance Authority (retired)](https://meteor-uat.aihw.gov.au/RegistrationAuthority/10), Retired 01/07/2016[Australian Commission on Safety and Quality in Health Care](https://meteor-uat.aihw.gov.au/RegistrationAuthority/2), Standard 23/11/2016 |

|  |
| --- |
| Collection and usage attributes |
| Population group age from: | 3 to 19 years20 to 44 years45 years and over |
| Computation description: |  Presented as a number per 100,000 people, age standardised, by Statistical Area Level 3.Analysis by Statistical Area Level 3 (SA3) is based on postcode of usual residence of the patient which is based on the patient's Medicare enrolment postcode on the date the prescription was dispensed.SA3s where the total population was less than 2,500 or where the population of interest was less than 200 are excluded.Suppression protocol for calculating age standardised rates:

|  |  |
| --- | --- |
|  Numerator | Total prescriptions dispensed were less than 20 (unrounded data) |
| Denominator | ERP for one or more five year age groups was less than 30 |

For the population group 3 to 19 years, the following age groups were used for calculating age standardised rates: 3-9, 10-14, 15-19. |
| Computation: | 100,000 x (Numerator ÷ Denominator), age standardisedFor more information about age-standardisation, see[/content/index.phtml/itemId/327276](https://meteor-uat.aihw.gov.au/content/327276) |
| Numerator: | Number of PBS prescriptions dispensed for asthma medicines in 2013-14. |
| Numerator data elements: | **Data Element / Data Set**[Pharmaceutical Benefits Scheme (PBS) prescription—PBS item prescribed, code NN[NNN]A](https://meteor-uat.aihw.gov.au/content/600778)**NMDS / DSS**[Pharmaceutical Benefits Scheme (PBS) state/territory data extract 2013-14](https://meteor-uat.aihw.gov.au/content/602524)**Guide for use**Data source type: Administrative by-product data

|  |  |
| --- | --- |
| **PBS code** | **Description** |
| 01034K | TERBUTALINE–Injection containing terbutaline sulfate 500 micrograms in 1 mL |
| 01099W | SALBUTAMOL–Capsule containing powder for oral inhalation 200 micrograms (as sulfate) (for use in Ventolin Rotahaler) |
| 01103C | SALBUTAMOL–Oral solution 2 mg (as sulfate) per 5 mL, 150 mL |
| 01252X | TERBUTALINE–Powder for oral inhalation in breath actuated device containing terbutaline sulfate 500 micrograms per dose, 200 doses |
| 01542E | IPRATROPIUM–Nebuliser solution containing ipratropium bromide 250 micrograms (anhydrous) in 1 mL single dose units, 30 |
| 02000G | SALBUTAMOL–Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 30 |
| 02001H | SALBUTAMOL–Nebuliser solution 5 mg (as sulfate) in 2.5 mL single dose units, 30 |
| 02003K | SALBUTAMOL–Nebuliser solution 5 mg (as sulfate) per mL, 30 mL |
| 02065Q | BUDESONIDE–Nebuliser suspension 500 micrograms in 2 mL single dose units, 30 |
| 02066R | BUDESONIDE–Nebuliser suspension 1 mg in 2 mL single dose units, 30 |
| 02070Y | BUDESONIDE–Powder for oral inhalation in breath actuated device 100 micrograms per dose, 200 doses |
| 02071B | BUDESONIDE–Powder for oral inhalation in breath actuated device 200 micrograms per dose, 200 doses |
| 02072C | BUDESONIDE–Powder for oral inhalation in breath actuated device 400 micrograms per dose, 200 doses |
| 02614N | THEOPHYLLINE–Oral solution 133.3 mg per 25 mL, 500 mL |
| 02634P | THEOPHYLLINE–Tablet 250 mg (sustained release) |
| 02817G | TERBUTALINE–Powder for oral inhalation in breath actuated device containing terbutaline sulfate 500 micrograms per dose, 100 doses |
| 02827T | FLUTICASONE + EFORMOTEROL–Pressurised inhalation containing fluticasone propionate 50 micrograms with eformoterol fumarate dihydrate 5 micrograms per dose, 120 doses |
| 02866W | BUDESONIDE + EFORMOTEROL–Pressurised inhalation containing budesonide 200 micrograms with eformoterol fumarate dihydrate 6 micrograms per dose, 120 doses, 2 |
| 02867X | BUDESONIDE + EFORMOTEROL–Pressurised inhalation containing budesonide 50 micrograms with eformoterol fumarate dihydrate 3 micrograms per dose, 120 doses, 2 |
| 02878L | CROMOGLYCATE–Capsule containing powder for oral inhalation containing sodium cromoglycate 20 mg (for use in Intal Spinhaler or Intal Halermatic) |
| 02938P | BUDESONIDE + EFORMOTEROL–Pressurised inhalation containing budesonide 100 micrograms with eformoterol fumarate dihydrate 3 micrograms per dose, 120 doses, 2 |
| 03491R | TERBUTALINE–Injection containing terbutaline sulfate 500 micrograms in 1 mL |
| 03495Y | SALBUTAMOL–Pressurised inhalation 100 micrograms (as sulfate) per dose, 200 doses (CFC-free formulation) |
| 03496B | SALBUTAMOL–Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 30 |
| 03497C | SALBUTAMOL–Nebuliser solution 5 mg (as sulfate) in 2.5 mL single dose units, 30 |
| 05134F | INDACATEROL–Capsule containing powder for oral inhalation 150 micrograms (as maleate) (for use in Breezhaler) |
| 05137J | INDACATEROL–Capsule containing powder for oral inhalation 300 micrograms (as maleate) (for use in Breezhaler) |
| 08136F | EFORMOTEROL–Capsule containing powder for oral inhalation containing eformoterol fumarate dihydrate 12 micrograms (for use in Foradile Aerolizer) |
| 08141L | SALMETEROL–Powder for oral inhalation in breath actuated device 50 micrograms (as xinafoate) per dose, 60 doses |
| 08147T | FLUTICASONE–Powder for oral inhalation in breath actuated device containing fluticasone propionate 100 micrograms per dose, 60 doses |
| 08148W | FLUTICASONE–Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms per dose, 60 doses |
| 08149X | FLUTICASONE–Powder for oral inhalation in breath actuated device containing fluticasone propionate 500 micrograms per dose, 60 doses |
| 08230E | THEOPHYLLINE–Tablet 200 mg (sustained release) |
| 08231F | THEOPHYLLINE–Tablet 300 mg (sustained release) |
| 08238N | IPRATROPIUM–Nebuliser solution containing ipratropium bromide 500 micrograms (anhydrous) in 1 mL single dose units, 30 |
| 08239P | EFORMOTEROL–Powder for oral inhalation in breath actuated device containing eformoterol fumarate dihydrate 6 micrograms per dose, 60 doses |
| 08240Q | EFORMOTEROL–Powder for oral inhalation in breath actuated device containing eformoterol fumarate dihydrate 12 micrograms per dose, 60 doses |
| 08288F | SALBUTAMOL–Pressurised inhalation 100 micrograms (as sulfate) per dose, 200 doses (CFC-free formulation) |
| 08334P | CROMOGLYCATE–Pressurised inhalation containing sodium cromoglycate 5 mg per dose, 112 doses (CFC-free formulation) |
| 08345F | FLUTICASONE–Pressurised inhalation containing fluticasone propionate 125 micrograms per dose, 120 doses (CFC-free formulation) |
| 08346G | FLUTICASONE–Pressurised inhalation containing fluticasone propionate 250 micrograms per dose, 120 doses (CFC-free formulation) |
| 08354Q | SALBUTAMOL–Pressurised inhalation in breath actuated device 100 micrograms (as sulfate) per dose, 200 doses (CFC-free formulation) |
| 08365G | NEDOCROMIL–Pressurised inhalation containing nedocromil sodium 2 mg per dose, 112 doses (CFC-free formulation) |
| 08406K | BECLOMETHASONE–Pressurised inhalation containing beclomethasone dipropionate 50 micrograms per dose, 200 doses (CFC-free formulation) |
| 08407L | BECLOMETHASONE–Pressurised inhalation containing beclomethasone dipropionate 100 micrograms per dose, 200 doses (CFC-free formulation) |
| 08408M | BECLOMETHASONE–Pressurised inhalation in breath actuated device containing beclomethasone dipropionate 50 micrograms per dose, 200 doses (CFC-free formulation) |
| 08409N | BECLOMETHASONE–Pressurised inhalation in breath actuated device containing beclomethasone dipropionate 100 micrograms per dose, 200 doses (CFC-free formulation) |
| 08430Q | FLUTICASONE + SALMETEROL–Powder for oral inhalation in breath actuated device containing fluticasone propionate 100 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses |
| 08431R | FLUTICASONE + SALMETEROL–Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses |
| 08432T | FLUTICASONE + SALMETEROL–Powder for oral inhalation in breath actuated device containing fluticasone propionate 500 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses |
| 08516F | FLUTICASONE–Pressurised inhalation containing fluticasone propionate 50 micrograms per dose, 120 doses (CFC-free formulation) |
| 08517G | FLUTICASONE + SALMETEROL–Pressurised inhalation containing fluticasone propionate 50 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation) |
| 08518H | FLUTICASONE + SALMETEROL–Pressurised inhalation containing fluticasone propionate 125 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation) |
| 08519J | FLUTICASONE + SALMETEROL–Pressurised inhalation containing fluticasone propionate 250 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation) |
| 08625Y | BUDESONIDE + EFORMOTEROL–Powder for oral inhalation in breath actuated device containing budesonide 200 micrograms with eformoterol fumarate dihydrate 6 micrograms per dose, 120 doses |
| 08627C | MONTELUKAST–Tablet, chewable, 4 mg (as sodium) |
| 08628D | MONTELUKAST–Tablet, chewable, 5 mg (as sodium) |
| 08671J | IPRATROPIUM–Pressurised inhalation containing ipratropium bromide 21 micrograms per dose, 200 doses (CFC-free formulation) |
| 08750M | BUDESONIDE + EFORMOTEROL–Powder for oral inhalation in breath actuated device containing budesonide 400 micrograms with eformoterol fumarate dihydrate 12 micrograms per dose, 60 doses, 2 |
| 08767K | CROMOGLYCATE–Pressurised inhalation containing sodium cromoglycate 1 mg per dose, 200 doses (CFC-free formulation) |
| 08796Y | BUDESONIDE + EFORMOTEROL–Powder for oral inhalation in breath actuated device containing budesonide 100 micrograms with eformoterol fumarate dihydrate 6 micrograms per dose, 120 doses |
| 08853Y | CICLESONIDE–Pressurised inhalation 80 micrograms per dose, 120 doses (CFC-free formulation) |
| 08854B | CICLESONIDE–Pressurised inhalation 160 micrograms per dose, 120 doses (CFC-free formulation) |
| 09745X | OMALIZUMAB–Powder for injection 150 mg with diluent |
| 09746Y | OMALIZUMAB–Powder for injection 150 mg with diluent |
| 10007Q | FLUTICASONE + EFORMOTEROL–Pressurised inhalation containing fluticasone propionate 125 micrograms with eformoterol fumarate dihydrate 5 micrograms per dose, 120 doses |
| 10008R | FLUTICASONE + EFORMOTEROL–Pressurised inhalation containing fluticasone propionate 250 micrograms with eformoterol fumarate dihydrate 10 micrograms per dose, 120 doses |
| 10015D | BUDESONIDE + EFORMOTEROL–Pressurised inhalation containing budesonide 100 micrograms with eformoterol fumarate dihydrate 3 micrograms per dose, 120 doses |
| 10018G | BUDESONIDE + EFORMOTEROL–Pressurised inhalation containing budesonide 200 micrograms with eformoterol fumarate dihydrate 6 micrograms per dose, 120 doses |
| 10024N | BUDESONIDE + EFORMOTEROL–Pressurised inhalation containing budesonide 50 micrograms with eformoterol fumarate dihydrate 3 micrograms per dose, 120 doses |
| 10059K | GLYCOPYRRONIUM–Capsule containing powder for oral inhalation 50 micrograms (as bromide) (for use in Breezhaler) |

 |
| Denominator: | Total population of age group |
| Denominator data elements: | **Data Element / Data Set**[Person—estimated resident population of Australia, total people N[N(7)]](https://meteor-uat.aihw.gov.au/content/388656)**Data Source**[ABS Estimated resident population (total population)](https://meteor-uat.aihw.gov.au/content/393625)**Guide for use**ABS Estimated resident population as at June 2001Data source type: Census based plus administrative by-product data |
| Disaggregation: | Statistical Area Level 3, which have been derived from [Postcode—Australian (person)](https://meteor-uat.aihw.gov.au/content/287224): * Statistical Area Level 3 (SA3s) are geographic areas defined in the ABS Australian Statistical Geography Standard (ASGS). The aim of SA3s is to create a standard framework for the analysis of ABS data at the regional level through clustering groups of SA2s that have similar regional characteristics. There are 333 spatial SA3s covering the whole of Australia without gaps or overlaps. They are designed to provide a regional breakdown of Australia. SA3s generally have a population of between 30,000 and 130,000 people. There are approximately 50 with fewer than 30,000 people and 35 with more than 130,000 as at 30 June 2011. For further information see the ABS publication, Australian Statistical Geography Standard (ASGS): Volume 1 – Main Structure and Greater Capital City Statistical Areas, July 2011 (cat. no. 1270.0.55.001).
 |
| Disaggregation data elements: | **Data Element / Data Set**[Person—age, total years N[NN]](https://meteor-uat.aihw.gov.au/content/303794)**NMDS / DSS**[COMPLETE - Pharmaceutical Benefits Scheme (PBS) Pharmacy claim script detail](https://meteor-uat.aihw.gov.au/content/601300)**Guide for use**Age of the person is based on the patient's Medicare enrolment date of birth and the date the prescription was dispensed.Data is disaggregated by the following age groups:* 3 to 19 years
* 20 to 44 years
* 45 and over.

 **Data Element / Data Set**[Address—Australian postcode, Australian postcode code (Postcode datafile) {NNNN}](https://meteor-uat.aihw.gov.au/content/429894)**NMDS / DSS**[COMPLETE - Pharmaceutical Benefits Scheme (PBS) Pharmacy claim script detail](https://meteor-uat.aihw.gov.au/content/601300)**Guide for use**Postcode is based on the patient's Medicare enrolement postcode on the date the prescription was dispensed.GPO postcodes 2001, 2124, 3001, 4001, 5001, 6843 excluded from the SA3 analysis but included in state/territory and national level analysis.Data source type: Administrative by-product dataUsed for disaggregation by Statistical Area Level 3. **Data Element / Data Set**[Address—statistical area, level 3 (SA3) code (ASGS 2011) NNNNN](https://meteor-uat.aihw.gov.au/content/457293) |
| Representational attributes |
| Representation class: | Rate |
| Data type: | Integer |
| Unit of measure: | Service event |
| Format: | NN[NNNN] |
| Data source attributes |
| Data sources: | **Data Source**[ABS Estimated resident population (total population)](https://meteor-uat.aihw.gov.au/content/393625)**Frequency**Quarterly**Data quality statement**[ABS Estimated resident population (total population), QS](https://meteor-uat.aihw.gov.au/content/449216)**Data custodian**Australian Bureau of Statistics |
| Accountability attributes |
| Reporting requirements: | Australian Commission of Safety and Quality in Health Care's Atlas of Healthcare Variation, released November 2015 |
| Organisation responsible for providing data: | Department of Health |
| Accountability: | Australian Commission of Safety and Quality in Health Care |
| Source and reference attributes |
| Submitting organisation: | National Health Performance Authority |